nodes	percent_of_prediction	percent_of_DWPC	metapath
Granisetron—CYP3A5—Teniposide—lymphatic system cancer	0.219	0.367	CbGbCtD
Granisetron—CYP3A5—Vincristine—lymphatic system cancer	0.105	0.176	CbGbCtD
Granisetron—CYP3A4—Cytarabine—lymphatic system cancer	0.0867	0.145	CbGbCtD
Granisetron—CYP3A4—Teniposide—lymphatic system cancer	0.0854	0.143	CbGbCtD
Granisetron—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0597	0.1	CbGbCtD
Granisetron—CYP3A4—Vincristine—lymphatic system cancer	0.0411	0.0688	CbGbCtD
Granisetron—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00137	0.00341	CcSEcCtD
Granisetron—Flushing—Bleomycin—lymphatic system cancer	0.00136	0.00337	CcSEcCtD
Granisetron—Feeling abnormal—Teniposide—lymphatic system cancer	0.00133	0.0033	CcSEcCtD
Granisetron—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00132	0.00328	CcSEcCtD
Granisetron—Chills—Bleomycin—lymphatic system cancer	0.00131	0.00326	CcSEcCtD
Granisetron—Sweating—Vincristine—lymphatic system cancer	0.0013	0.00324	CcSEcCtD
Granisetron—Nausea—Mechlorethamine—lymphatic system cancer	0.0013	0.00323	CcSEcCtD
Granisetron—Hyperbilirubinaemia—Methotrexate—lymphatic system cancer	0.0013	0.00322	CcSEcCtD
Granisetron—Alopecia—Bleomycin—lymphatic system cancer	0.00129	0.00321	CcSEcCtD
Granisetron—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00129	0.00321	CcSEcCtD
Granisetron—Jaundice—Mitoxantrone—lymphatic system cancer	0.00129	0.0032	CcSEcCtD
Granisetron—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00129	0.0032	CcSEcCtD
Granisetron—Urticaria—Teniposide—lymphatic system cancer	0.00128	0.00319	CcSEcCtD
Granisetron—Oliguria—Methotrexate—lymphatic system cancer	0.00128	0.00318	CcSEcCtD
Granisetron—Abdominal pain—Teniposide—lymphatic system cancer	0.00128	0.00317	CcSEcCtD
Granisetron—Body temperature increased—Teniposide—lymphatic system cancer	0.00128	0.00317	CcSEcCtD
Granisetron—Paraesthesia—Fludarabine—lymphatic system cancer	0.00127	0.00316	CcSEcCtD
Granisetron—Sweating—Mitoxantrone—lymphatic system cancer	0.00127	0.00315	CcSEcCtD
Granisetron—Dyspnoea—Fludarabine—lymphatic system cancer	0.00126	0.00314	CcSEcCtD
Granisetron—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00126	0.00312	CcSEcCtD
Granisetron—Dyspepsia—Fludarabine—lymphatic system cancer	0.00125	0.0031	CcSEcCtD
Granisetron—Hepatic enzyme increased—Methotrexate—lymphatic system cancer	0.00125	0.0031	CcSEcCtD
Granisetron—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00124	0.00308	CcSEcCtD
Granisetron—Decreased appetite—Fludarabine—lymphatic system cancer	0.00123	0.00306	CcSEcCtD
Granisetron—Visual impairment—Carmustine—lymphatic system cancer	0.00123	0.00306	CcSEcCtD
Granisetron—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00122	0.00304	CcSEcCtD
Granisetron—Pain—Fludarabine—lymphatic system cancer	0.00121	0.00301	CcSEcCtD
Granisetron—Constipation—Fludarabine—lymphatic system cancer	0.00121	0.00301	CcSEcCtD
Granisetron—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00121	0.003	CcSEcCtD
Granisetron—Connective tissue disorder—Vincristine—lymphatic system cancer	0.0012	0.00298	CcSEcCtD
Granisetron—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00119	0.00296	CcSEcCtD
Granisetron—Hypersensitivity—Teniposide—lymphatic system cancer	0.00119	0.00295	CcSEcCtD
Granisetron—Flushing—Carmustine—lymphatic system cancer	0.00119	0.00295	CcSEcCtD
Granisetron—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00118	0.00294	CcSEcCtD
Granisetron—Anaemia—Bleomycin—lymphatic system cancer	0.00118	0.00293	CcSEcCtD
Granisetron—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00117	0.0029	CcSEcCtD
Granisetron—Asthenia—Teniposide—lymphatic system cancer	0.00116	0.00288	CcSEcCtD
Granisetron—Melaena—Methotrexate—lymphatic system cancer	0.00115	0.00286	CcSEcCtD
Granisetron—Malaise—Bleomycin—lymphatic system cancer	0.00115	0.00285	CcSEcCtD
Granisetron—Pruritus—Teniposide—lymphatic system cancer	0.00114	0.00284	CcSEcCtD
Granisetron—Arrhythmia—Carmustine—lymphatic system cancer	0.00114	0.00284	CcSEcCtD
Granisetron—Leukopenia—Bleomycin—lymphatic system cancer	0.00114	0.00283	CcSEcCtD
Granisetron—Alopecia—Carmustine—lymphatic system cancer	0.00113	0.0028	CcSEcCtD
Granisetron—Body temperature increased—Fludarabine—lymphatic system cancer	0.00112	0.00279	CcSEcCtD
Granisetron—Malnutrition—Carmustine—lymphatic system cancer	0.00111	0.00276	CcSEcCtD
Granisetron—Cough—Bleomycin—lymphatic system cancer	0.00111	0.00276	CcSEcCtD
Granisetron—Angiopathy—Vincristine—lymphatic system cancer	0.00111	0.00275	CcSEcCtD
Granisetron—Diarrhoea—Teniposide—lymphatic system cancer	0.0011	0.00274	CcSEcCtD
Granisetron—Chest pain—Bleomycin—lymphatic system cancer	0.00109	0.0027	CcSEcCtD
Granisetron—Alopecia—Vincristine—lymphatic system cancer	0.00108	0.00268	CcSEcCtD
Granisetron—Coma—Methotrexate—lymphatic system cancer	0.00108	0.00268	CcSEcCtD
Granisetron—Discomfort—Bleomycin—lymphatic system cancer	0.00107	0.00266	CcSEcCtD
Granisetron—Chills—Mitoxantrone—lymphatic system cancer	0.00107	0.00265	CcSEcCtD
Granisetron—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00106	0.00264	CcSEcCtD
Granisetron—Alopecia—Mitoxantrone—lymphatic system cancer	0.00105	0.00261	CcSEcCtD
Granisetron—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00105	0.0026	CcSEcCtD
Granisetron—Tremor—Carmustine—lymphatic system cancer	0.00104	0.00259	CcSEcCtD
Granisetron—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00104	0.00258	CcSEcCtD
Granisetron—Oedema—Bleomycin—lymphatic system cancer	0.00104	0.00258	CcSEcCtD
Granisetron—Infection—Bleomycin—lymphatic system cancer	0.00103	0.00257	CcSEcCtD
Granisetron—Anaemia—Carmustine—lymphatic system cancer	0.00103	0.00255	CcSEcCtD
Granisetron—Vomiting—Teniposide—lymphatic system cancer	0.00103	0.00255	CcSEcCtD
Granisetron—Agitation—Carmustine—lymphatic system cancer	0.00102	0.00254	CcSEcCtD
Granisetron—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00102	0.00253	CcSEcCtD
Granisetron—Asthenia—Fludarabine—lymphatic system cancer	0.00102	0.00253	CcSEcCtD
Granisetron—Rash—Teniposide—lymphatic system cancer	0.00102	0.00253	CcSEcCtD
Granisetron—Dermatitis—Teniposide—lymphatic system cancer	0.00102	0.00253	CcSEcCtD
Granisetron—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00101	0.00252	CcSEcCtD
Granisetron—Headache—Teniposide—lymphatic system cancer	0.00101	0.00251	CcSEcCtD
Granisetron—Pruritus—Fludarabine—lymphatic system cancer	0.001	0.00249	CcSEcCtD
Granisetron—Leukopenia—Carmustine—lymphatic system cancer	0.000996	0.00247	CcSEcCtD
Granisetron—Anaemia—Vincristine—lymphatic system cancer	0.000982	0.00244	CcSEcCtD
Granisetron—Agitation—Vincristine—lymphatic system cancer	0.000976	0.00242	CcSEcCtD
Granisetron—Photosensitivity—Methotrexate—lymphatic system cancer	0.000975	0.00242	CcSEcCtD
Granisetron—Hypotension—Bleomycin—lymphatic system cancer	0.000972	0.00241	CcSEcCtD
Granisetron—Diarrhoea—Fludarabine—lymphatic system cancer	0.000971	0.00241	CcSEcCtD
Granisetron—Hypertension—Carmustine—lymphatic system cancer	0.000961	0.00239	CcSEcCtD
Granisetron—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00096	0.00238	CcSEcCtD
Granisetron—Nausea—Teniposide—lymphatic system cancer	0.000959	0.00238	CcSEcCtD
Granisetron—Anaemia—Mitoxantrone—lymphatic system cancer	0.000956	0.00237	CcSEcCtD
Granisetron—Vertigo—Vincristine—lymphatic system cancer	0.000954	0.00237	CcSEcCtD
Granisetron—Leukopenia—Vincristine—lymphatic system cancer	0.000951	0.00236	CcSEcCtD
Granisetron—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000948	0.00235	CcSEcCtD
Granisetron—Chest pain—Carmustine—lymphatic system cancer	0.000947	0.00235	CcSEcCtD
Granisetron—Anxiety—Carmustine—lymphatic system cancer	0.000944	0.00234	CcSEcCtD
Granisetron—Paraesthesia—Bleomycin—lymphatic system cancer	0.000934	0.00232	CcSEcCtD
Granisetron—Malaise—Mitoxantrone—lymphatic system cancer	0.000933	0.00232	CcSEcCtD
Granisetron—Dyspnoea—Bleomycin—lymphatic system cancer	0.000927	0.0023	CcSEcCtD
Granisetron—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000926	0.0023	CcSEcCtD
Granisetron—Hypertension—Vincristine—lymphatic system cancer	0.000917	0.00228	CcSEcCtD
Granisetron—Oedema—Carmustine—lymphatic system cancer	0.000908	0.00226	CcSEcCtD
Granisetron—Decreased appetite—Bleomycin—lymphatic system cancer	0.000904	0.00225	CcSEcCtD
Granisetron—Cough—Mitoxantrone—lymphatic system cancer	0.000903	0.00224	CcSEcCtD
Granisetron—Infection—Carmustine—lymphatic system cancer	0.000902	0.00224	CcSEcCtD
Granisetron—Vomiting—Fludarabine—lymphatic system cancer	0.000902	0.00224	CcSEcCtD
Granisetron—Rash—Fludarabine—lymphatic system cancer	0.000895	0.00222	CcSEcCtD
Granisetron—Dermatitis—Fludarabine—lymphatic system cancer	0.000894	0.00222	CcSEcCtD
Granisetron—Hypertension—Mitoxantrone—lymphatic system cancer	0.000893	0.00222	CcSEcCtD
Granisetron—Pain—Bleomycin—lymphatic system cancer	0.00089	0.00221	CcSEcCtD
Granisetron—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000889	0.00221	CcSEcCtD
Granisetron—Headache—Fludarabine—lymphatic system cancer	0.000889	0.00221	CcSEcCtD
Granisetron—Tachycardia—Carmustine—lymphatic system cancer	0.000886	0.0022	CcSEcCtD
Granisetron—Chest pain—Mitoxantrone—lymphatic system cancer	0.000881	0.00219	CcSEcCtD
Granisetron—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000881	0.00219	CcSEcCtD
Granisetron—Anxiety—Mitoxantrone—lymphatic system cancer	0.000878	0.00218	CcSEcCtD
Granisetron—Discomfort—Mitoxantrone—lymphatic system cancer	0.00087	0.00216	CcSEcCtD
Granisetron—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000867	0.00215	CcSEcCtD
Granisetron—Oedema—Vincristine—lymphatic system cancer	0.000867	0.00215	CcSEcCtD
Granisetron—Infection—Vincristine—lymphatic system cancer	0.000861	0.00214	CcSEcCtD
Granisetron—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000857	0.00213	CcSEcCtD
Granisetron—Nervous system disorder—Vincristine—lymphatic system cancer	0.00085	0.00211	CcSEcCtD
Granisetron—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000849	0.00211	CcSEcCtD
Granisetron—Hypotension—Carmustine—lymphatic system cancer	0.000849	0.00211	CcSEcCtD
Granisetron—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000844	0.0021	CcSEcCtD
Granisetron—Oedema—Mitoxantrone—lymphatic system cancer	0.000844	0.0021	CcSEcCtD
Granisetron—Nausea—Fludarabine—lymphatic system cancer	0.000843	0.00209	CcSEcCtD
Granisetron—Infection—Mitoxantrone—lymphatic system cancer	0.000839	0.00208	CcSEcCtD
Granisetron—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000838	0.00208	CcSEcCtD
Granisetron—Shock—Mitoxantrone—lymphatic system cancer	0.000831	0.00206	CcSEcCtD
Granisetron—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000827	0.00205	CcSEcCtD
Granisetron—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000827	0.00205	CcSEcCtD
Granisetron—Urticaria—Bleomycin—lymphatic system cancer	0.000826	0.00205	CcSEcCtD
Granisetron—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000824	0.00205	CcSEcCtD
Granisetron—Body temperature increased—Bleomycin—lymphatic system cancer	0.000822	0.00204	CcSEcCtD
Granisetron—Insomnia—Carmustine—lymphatic system cancer	0.000821	0.00204	CcSEcCtD
Granisetron—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00082	0.00204	CcSEcCtD
Granisetron—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000816	0.00203	CcSEcCtD
Granisetron—Paraesthesia—Carmustine—lymphatic system cancer	0.000815	0.00203	CcSEcCtD
Granisetron—Hypotension—Vincristine—lymphatic system cancer	0.00081	0.00201	CcSEcCtD
Granisetron—Dyspnoea—Carmustine—lymphatic system cancer	0.00081	0.00201	CcSEcCtD
Granisetron—Somnolence—Carmustine—lymphatic system cancer	0.000807	0.002	CcSEcCtD
Granisetron—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.00079	0.00196	CcSEcCtD
Granisetron—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00079	0.00196	CcSEcCtD
Granisetron—Decreased appetite—Carmustine—lymphatic system cancer	0.000789	0.00196	CcSEcCtD
Granisetron—Hypotension—Mitoxantrone—lymphatic system cancer	0.000789	0.00196	CcSEcCtD
Granisetron—Insomnia—Vincristine—lymphatic system cancer	0.000784	0.00195	CcSEcCtD
Granisetron—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000784	0.00195	CcSEcCtD
Granisetron—Paraesthesia—Vincristine—lymphatic system cancer	0.000778	0.00193	CcSEcCtD
Granisetron—Pain—Carmustine—lymphatic system cancer	0.000777	0.00193	CcSEcCtD
Granisetron—Constipation—Carmustine—lymphatic system cancer	0.000777	0.00193	CcSEcCtD
Granisetron—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000769	0.00191	CcSEcCtD
Granisetron—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000766	0.0019	CcSEcCtD
Granisetron—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000758	0.00188	CcSEcCtD
Granisetron—Decreased appetite—Vincristine—lymphatic system cancer	0.000754	0.00187	CcSEcCtD
Granisetron—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000753	0.00187	CcSEcCtD
Granisetron—Somnolence—Mitoxantrone—lymphatic system cancer	0.00075	0.00186	CcSEcCtD
Granisetron—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000748	0.00186	CcSEcCtD
Granisetron—Feeling abnormal—Carmustine—lymphatic system cancer	0.000748	0.00186	CcSEcCtD
Granisetron—Asthenia—Bleomycin—lymphatic system cancer	0.000746	0.00185	CcSEcCtD
Granisetron—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000743	0.00185	CcSEcCtD
Granisetron—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000743	0.00184	CcSEcCtD
Granisetron—Constipation—Vincristine—lymphatic system cancer	0.000741	0.00184	CcSEcCtD
Granisetron—Pain—Vincristine—lymphatic system cancer	0.000741	0.00184	CcSEcCtD
Granisetron—Pruritus—Bleomycin—lymphatic system cancer	0.000736	0.00183	CcSEcCtD
Granisetron—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000734	0.00182	CcSEcCtD
Granisetron—Eosinophilia—Methotrexate—lymphatic system cancer	0.000732	0.00182	CcSEcCtD
Granisetron—Pain—Mitoxantrone—lymphatic system cancer	0.000722	0.00179	CcSEcCtD
Granisetron—Constipation—Mitoxantrone—lymphatic system cancer	0.000722	0.00179	CcSEcCtD
Granisetron—Body temperature increased—Carmustine—lymphatic system cancer	0.000718	0.00178	CcSEcCtD
Granisetron—Abdominal pain—Carmustine—lymphatic system cancer	0.000718	0.00178	CcSEcCtD
Granisetron—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000709	0.00176	CcSEcCtD
Granisetron—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000696	0.00173	CcSEcCtD
Granisetron—Dysuria—Methotrexate—lymphatic system cancer	0.000692	0.00172	CcSEcCtD
Granisetron—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00069	0.00171	CcSEcCtD
Granisetron—Abdominal pain—Vincristine—lymphatic system cancer	0.000685	0.0017	CcSEcCtD
Granisetron—Body temperature increased—Vincristine—lymphatic system cancer	0.000685	0.0017	CcSEcCtD
Granisetron—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000675	0.00168	CcSEcCtD
Granisetron—Urticaria—Mitoxantrone—lymphatic system cancer	0.000671	0.00167	CcSEcCtD
Granisetron—Hypersensitivity—Carmustine—lymphatic system cancer	0.000669	0.00166	CcSEcCtD
Granisetron—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000667	0.00166	CcSEcCtD
Granisetron—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000667	0.00166	CcSEcCtD
Granisetron—Vomiting—Bleomycin—lymphatic system cancer	0.000661	0.00164	CcSEcCtD
Granisetron—Rash—Bleomycin—lymphatic system cancer	0.000656	0.00163	CcSEcCtD
Granisetron—Dermatitis—Bleomycin—lymphatic system cancer	0.000655	0.00163	CcSEcCtD
Granisetron—Asthenia—Carmustine—lymphatic system cancer	0.000652	0.00162	CcSEcCtD
Granisetron—Hypersensitivity—Vincristine—lymphatic system cancer	0.000639	0.00159	CcSEcCtD
Granisetron—Sweating—Methotrexate—lymphatic system cancer	0.000632	0.00157	CcSEcCtD
Granisetron—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000624	0.00155	CcSEcCtD
Granisetron—Epistaxis—Methotrexate—lymphatic system cancer	0.000622	0.00154	CcSEcCtD
Granisetron—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000622	0.00154	CcSEcCtD
Granisetron—Asthenia—Vincristine—lymphatic system cancer	0.000622	0.00154	CcSEcCtD
Granisetron—Diarrhoea—Carmustine—lymphatic system cancer	0.000621	0.00154	CcSEcCtD
Granisetron—Nausea—Bleomycin—lymphatic system cancer	0.000618	0.00153	CcSEcCtD
Granisetron—Asthenia—Mitoxantrone—lymphatic system cancer	0.000606	0.0015	CcSEcCtD
Granisetron—Dizziness—Carmustine—lymphatic system cancer	0.0006	0.00149	CcSEcCtD
Granisetron—Diarrhoea—Vincristine—lymphatic system cancer	0.000593	0.00147	CcSEcCtD
Granisetron—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000578	0.00143	CcSEcCtD
Granisetron—Vomiting—Carmustine—lymphatic system cancer	0.000577	0.00143	CcSEcCtD
Granisetron—Dizziness—Vincristine—lymphatic system cancer	0.000573	0.00142	CcSEcCtD
Granisetron—Rash—Carmustine—lymphatic system cancer	0.000573	0.00142	CcSEcCtD
Granisetron—Dermatitis—Carmustine—lymphatic system cancer	0.000572	0.00142	CcSEcCtD
Granisetron—Visual impairment—Methotrexate—lymphatic system cancer	0.000571	0.00142	CcSEcCtD
Granisetron—Headache—Carmustine—lymphatic system cancer	0.000569	0.00141	CcSEcCtD
Granisetron—Vomiting—Vincristine—lymphatic system cancer	0.000551	0.00137	CcSEcCtD
Granisetron—Rash—Vincristine—lymphatic system cancer	0.000547	0.00136	CcSEcCtD
Granisetron—Dermatitis—Vincristine—lymphatic system cancer	0.000546	0.00136	CcSEcCtD
Granisetron—Headache—Vincristine—lymphatic system cancer	0.000543	0.00135	CcSEcCtD
Granisetron—Nausea—Carmustine—lymphatic system cancer	0.000539	0.00134	CcSEcCtD
Granisetron—Angiopathy—Methotrexate—lymphatic system cancer	0.000537	0.00133	CcSEcCtD
Granisetron—Vomiting—Mitoxantrone—lymphatic system cancer	0.000537	0.00133	CcSEcCtD
Granisetron—Rash—Mitoxantrone—lymphatic system cancer	0.000532	0.00132	CcSEcCtD
Granisetron—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000532	0.00132	CcSEcCtD
Granisetron—Chills—Methotrexate—lymphatic system cancer	0.000531	0.00132	CcSEcCtD
Granisetron—Headache—Mitoxantrone—lymphatic system cancer	0.000529	0.00131	CcSEcCtD
Granisetron—Alopecia—Methotrexate—lymphatic system cancer	0.000523	0.0013	CcSEcCtD
Granisetron—Malnutrition—Methotrexate—lymphatic system cancer	0.000515	0.00128	CcSEcCtD
Granisetron—Nausea—Vincristine—lymphatic system cancer	0.000515	0.00128	CcSEcCtD
Granisetron—Dysgeusia—Methotrexate—lymphatic system cancer	0.000505	0.00125	CcSEcCtD
Granisetron—Nausea—Mitoxantrone—lymphatic system cancer	0.000501	0.00125	CcSEcCtD
Granisetron—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000478	0.00119	CcSEcCtD
Granisetron—Anaemia—Methotrexate—lymphatic system cancer	0.000476	0.00118	CcSEcCtD
Granisetron—Malaise—Methotrexate—lymphatic system cancer	0.000465	0.00115	CcSEcCtD
Granisetron—Vertigo—Methotrexate—lymphatic system cancer	0.000463	0.00115	CcSEcCtD
Granisetron—Leukopenia—Methotrexate—lymphatic system cancer	0.000461	0.00115	CcSEcCtD
Granisetron—Cough—Methotrexate—lymphatic system cancer	0.00045	0.00112	CcSEcCtD
Granisetron—Chest pain—Methotrexate—lymphatic system cancer	0.000439	0.00109	CcSEcCtD
Granisetron—Arthralgia—Methotrexate—lymphatic system cancer	0.000439	0.00109	CcSEcCtD
Granisetron—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000436	0.00108	CcSEcCtD
Granisetron—Discomfort—Methotrexate—lymphatic system cancer	0.000433	0.00108	CcSEcCtD
Granisetron—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000421	0.00104	CcSEcCtD
Granisetron—Infection—Methotrexate—lymphatic system cancer	0.000418	0.00104	CcSEcCtD
Granisetron—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000412	0.00102	CcSEcCtD
Granisetron—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000412	0.00102	CcSEcCtD
Granisetron—Skin disorder—Methotrexate—lymphatic system cancer	0.000409	0.00101	CcSEcCtD
Granisetron—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000407	0.00101	CcSEcCtD
Granisetron—Hypotension—Methotrexate—lymphatic system cancer	0.000393	0.000976	CcSEcCtD
Granisetron—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000383	0.000952	CcSEcCtD
Granisetron—Insomnia—Methotrexate—lymphatic system cancer	0.00038	0.000945	CcSEcCtD
Granisetron—Paraesthesia—Methotrexate—lymphatic system cancer	0.000378	0.000938	CcSEcCtD
Granisetron—Dyspnoea—Methotrexate—lymphatic system cancer	0.000375	0.000931	CcSEcCtD
Granisetron—Somnolence—Methotrexate—lymphatic system cancer	0.000374	0.000929	CcSEcCtD
Granisetron—Dyspepsia—Methotrexate—lymphatic system cancer	0.00037	0.000919	CcSEcCtD
Granisetron—Decreased appetite—Methotrexate—lymphatic system cancer	0.000366	0.000908	CcSEcCtD
Granisetron—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000363	0.000902	CcSEcCtD
Granisetron—Pain—Methotrexate—lymphatic system cancer	0.00036	0.000893	CcSEcCtD
Granisetron—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000347	0.000861	CcSEcCtD
Granisetron—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000344	0.000854	CcSEcCtD
Granisetron—Urticaria—Methotrexate—lymphatic system cancer	0.000334	0.00083	CcSEcCtD
Granisetron—Body temperature increased—Methotrexate—lymphatic system cancer	0.000332	0.000826	CcSEcCtD
Granisetron—Abdominal pain—Methotrexate—lymphatic system cancer	0.000332	0.000826	CcSEcCtD
Granisetron—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00031	0.00077	CcSEcCtD
Granisetron—Asthenia—Methotrexate—lymphatic system cancer	0.000302	0.000749	CcSEcCtD
Granisetron—Pruritus—Methotrexate—lymphatic system cancer	0.000298	0.000739	CcSEcCtD
Granisetron—Diarrhoea—Methotrexate—lymphatic system cancer	0.000288	0.000715	CcSEcCtD
Granisetron—Dizziness—Methotrexate—lymphatic system cancer	0.000278	0.000691	CcSEcCtD
Granisetron—Vomiting—Methotrexate—lymphatic system cancer	0.000267	0.000664	CcSEcCtD
Granisetron—Rash—Methotrexate—lymphatic system cancer	0.000265	0.000659	CcSEcCtD
Granisetron—Dermatitis—Methotrexate—lymphatic system cancer	0.000265	0.000658	CcSEcCtD
Granisetron—Headache—Methotrexate—lymphatic system cancer	0.000263	0.000654	CcSEcCtD
Granisetron—Nausea—Methotrexate—lymphatic system cancer	0.00025	0.00062	CcSEcCtD
